<i>CEBPA</i> Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations

Ngā tūemi rite

• Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
  mā: Stefan Fröhling, me ētahi atu.
  I whakaputaina: (2002)
• Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
  mā: Konstanze Döhner, me ētahi atu.
  I whakaputaina: (2005)
• Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
  mā: Richard F. Schlenk, me ētahi atu.
  I whakaputaina: (2008)
• Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B
  mā: Stefan Fröhling, me ētahi atu.
  I whakaputaina: (2006)
• Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
  mā: Erdogan Taskesen, me ētahi atu.
  I whakaputaina: (2010)